Breaking News

Astex Earns Novartis Milestone

By Kristin Brooks | March 5, 2014

Initiates Phase III trial of LEE011 in advanced breast cancer

Astex Pharmaceuticals has received a milestone payment from Novartis for the commencement, by Novartis, of a Phase III trial of LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4 and 6 in postmenopausal woman with advanced breast cancer. LEE011 was discovered under a drug discovery collaboration between Astex and Novartis initiated in December 2005.
 
LEE011 inhibits CDK4 and CDK6 leading to cell cycle arrest and suppression of DNA synthesis, which may inhibit cancer cell growth. LEE011, in combination with other agents, has shown promising activity in preclinical studies in melanoma and breast cancer.
 

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent